China Issues Limited Circulation Permit for Antibody Drugs

jpnn.com, CHINA - China's drug authority issued a limited distribution permit for antibody drugs manufactured by a pharmaceutical institution headquartered in Beijing.

These drugs can be obtained in clinics to prevent patients from being referred to the hospital and increase the chances of survival for high-risk patients.

This was the first drug that could neutralize antibodies with independent intellectual property rights approved by Chinese authorities, local media monitored by ANTARA in Beijing said on Friday.

In its announcement, China's National Medical Products Agency (NMPA) said it had approved two antibody-neutralizing therapeutic drugs.

However, the permit is limited to emergency situations that can be used for the treatment and care of adult and adolescent patients aged 12 to 17 years weighing more than 40 kilograms.

The approval is issued at a time when the world is facing a wave of Omicron Covid-19 variant.

China is currently facing various studies that show the efficacy of domestic vaccines is lower than foreign vaccines.

The NMPA issues marketing authorizations for monoclonal antibody treatments.